Kevin Harrington: Novel Radiosensitising Agent With Palliative Dose Radiotherapy
Kevin Harrington, Professor in Biological Cancer Therapies at Institute of Cancer Research, shared a post on LinkedIn about a recent article he and his colleagues co-authored published in Nature Communications:
“I am delighted to announce the publication of the latest research from our team in the Division of Radiotherapy and Imaging at The Institute of Cancer Research. The PATRIOT Part C trial represents the culmination of a long, and sometimes bumpy, road in completing a study of a novel radiosensitising agent (ATR inhibitor, ceralasertib) with palliative dose radiotherapy.
The drug exerts remarkable effects in sensitising cancers to modest doses of palliative radiotherapy and also modulates the immune response intratumourally and systemically. This drug has the potential to be a potent anti-cancer drug alone and in combination with chemotherapy, immunotherapy or radiotherapy.
The dedication of Dr Magnus Dillon in delivering this study deserves particular mention. Throughout many years of delivering Parts A, B and C of the PATRIOT project, Magnus has led both the clinical care of patients and the laboratory translational studies.
During this period, he has also published seminal laboratory work addressing issues related to the effect of radiotherapy on anti-cancer immune responses. He has now set up own independent research group in gastro-intestinal oncology and will continue to make huge contributions to the research field in what I hope will be a long and illustrious career.
Professor Mark Saunders did an outstanding job in chairing the Safety Monitoring Committee and Professor Udai Banerji gave invaluable support to that committee and also to the biomarker analysis work.
I also wish to thank Simon Smith at Astra-Zeneca who has given us steadfast support, even during challenging times (e.g. the COVID pandemic).
We thank Cancer Research UK, the ICR/RM NIHR Biomedical Research Centre, the ECMC, The Taylor Family Foundation, Rosetrees Trust, CRIS Cancer Foundation and Paul and Kathy Beaumont for funding support for this work.
Ultimately, the greatest thanks lie with the remarkable people who agreed to participate in this study. Without the support of the patients and their families and carers, the insights we have gained here would not have been possible.”
Title: Tumor control and immune activation through palliative irradiation and ATR inhibition, PATRIOT Part C: a phase Ib trial
Authors: Magnus T. Dillon, Emmanuel C. Patin, Kabir Mohammed, Jeane Guevara, Simon A. Smith, Emma Dean, Heba Soliman, Pablo Nenclares, Motoko Ryugenji, Davina Northcote, Neel Shah, Lorna Grove, Christopher J. Lord, Stephen Pettit, Matt Tall, Karen E. Swales, Udai Banerji, Alan A. Melcher, Mark Saunders, Martin D. Forster, Kevin J. Harrington
Read the Full Article on Nature Communications
More posts featuring Kevin Harrington.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023